Philip Coelho Biography and Net Worth

Philip H. Coelho, Founder and Chief Technology Officer (CTO)of Thermogenesis Corp., is an engineer and inventor, educated at the University of California, Davis, where he specialized in thermodynamics and machine design. He holds more than 40 U.S. patents related to cell selection, cell cryopreservation, cell washing, automated cryogenic freezing and storage of cells and harvesting clotting proteins from blood. As Founder, Chairman and CEO of Thermogenesis Corp., Mr. Coelho developed the Thermoline ultra rapid blood plasma freezer and thawer; the CryoSeal automated system for preparing fibrin sealant from a surgical patient’s blood; the BioArchive robotic system for controlled-rate freezing and cryogenically archiving units of hematopoietic stem and progenitor cells (HSPCs) derived from placental/cord blood; and the AutoXpress System, which automates harvesting of HSPCs from cord blood into a 25 ml dual-compartment freezing bag. The BioArchive and AutoXpress Systems have established the highest quality GMP standards in cord blood processing and banking worldwide. Mr. Coelho retired from Thermogenesis Corp in August 2007. In 2009, Mr. Coelho co-founded SynGen Inc., and began the development of programmable systems that improve the speed and efficiency of the isolation and capture of purified stem, progenitor and immune cells residing within peripheral or placental/cord blood, bone marrow aspirate and leukapheresis. In July 2017, SynGen merged with Thermogenesis Corp, now a subsidiary of Cesca Therapeutics, and Mr. Coelho accepted the position of CTO in the combined company. He is now leading the development of CAR-TXpress, an automated method of manufacturing therapeutic doses of CAR T-cells in a functionally closed cell processing system. Mr. Coelho has been a member of the Catalyst Board of Directors since October 2002.